HER2 targeting chimeric antigen receptor T cell therapy (Essen Biotech)

N/A

Report date: 2025/07/23 11:38:23

Base Information

Drug NameHER2 targeting chimeric antigen receptor T cell therapy (Essen Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSarcomaSarcoma, SynovialSarcoma, Ewing +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesEssen Biotech

China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech

Inactive CompaniesN/A

Active IndicationsSarcomaSarcoma, SynovialSarcoma, Ewing +[5]

Inactive IndicationsN/A

Other Information

ATC CodeN/A